U.S. market Closed. Opens in 17 hours 15 minutes

CCCC | C4 Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
Revenue20.76M31.10M45.78M33.20M21.38M19.36M
Cost of Revenue7.74M7.57M2.91M77.47M47.66MN/A
Gross Profit13.02M23.52M42.88M-44.27M-26.28M19.36M
Operating Expenses152.05M160.63M127.92M93.64M56.83M35.75M
Selling, General & Admin34.34M42.79M33.25M15.20M8.77M7.16M
Research & Development117.71M117.84M94.67M78.44M48.06M28.59M
Other Operating ExpensesN/AN/AN/AN/A325.00K-7.00K
Operating Income-139.03M-129.53M-82.13M-60.45M-35.45M-16.39M
Other Expenses / Income7.82M1.36M-1.76M-6.51M2.16M-7.00K
Before Tax Income-131.21M-128.18M-83.89M-66.96M-33.30M-15.71M
Income Tax Expenses1.28M-1.68M2.15M-626.00K804.00K678.00K
Net Income-132.49M-126.50M-86.04M-66.33M-34.10M-15.71M
Interest Expenses1.37M2.22M2.15M1.23MN/AN/A
Basic Shares Outstanding49.64M48.86M46.04M43.06M42.99M14.79M
Diluted Shares Outstanding49.64M48.86M46.04M43.06M42.99M14.79M
EBITDA-131.29M-125.96M-80.25M-58.44M-33.86M-15.12M
EBITDA Margin-632.56%-405.06%-175.29%-176.05%-158.35%-78.06%
EBIT-129.84M-125.96M-81.75M-65.73M-33.30M-15.03M
EBIT Margin-625.55%-405.06%-178.55%-198.02%-155.72%-77.63%
Financial Year End2023-12-312022-12-312021-12-312020-12-312019-12-312018-12-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙